Publications by authors named "Erik Duijvelaar"
Deep phenotyping of pulmonary edema and pulmonary vascular permeability in COVID-19 ARDS.
Am J Physiol Lung Cell Mol Physiol
January 2025
Article Synopsis
Article Synopsis
- * In a clinical trial involving 385 COVID-19 patients, the tyrosine kinase inhibitor imatinib was found to significantly reduce severe hyperglycaemia compared to a placebo, despite not affecting insulin production or central insulin sensitivity.
- * Imatinib treatment also led to increased levels of beneficial proteins like angiotensin-2 and adiponectin, while lowering inflammatory markers, indicating it may help restore glucose regulation in COVID-19 patients.
Article Synopsis
- COVID-19 can cause serious breathing problems due to how the virus affects the body and how the immune system reacts to it.
- A treatment called imatinib may help patients breathe better and reduce the time they need help with machines.
- Researchers studied blood proteins from many patients to find out which ones help predict serious illness and see how imatinib affects these proteins in COVID-19 patients.
Article Synopsis
- - The study evaluated the effects of intravenous imatinib on patients with acute respiratory distress syndrome (ARDS) caused by COVID-19, focusing on its ability to reduce pulmonary edema.
- - In a randomized trial involving 66 patients, results showed no significant difference in pulmonary edema reduction or clinical outcomes between imatinib and placebo groups, although imatinib was found to be safe.
- - Interestingly, a subset of patients with high levels of specific inflammatory markers did benefit from imatinib treatment, indicating that targeted approaches may improve outcomes in certain ARDS patients.
Article Synopsis
- The CounterCOVID study demonstrated that oral imatinib treatment resulted in improved clinical outcomes and reduced mortality in COVID-19 patients compared to a placebo, with notable elevated levels of alpha-1 acid glycoprotein (AAG) impacting drug concentrations.
- This post-hoc analysis aimed to compare the drug exposure of imatinib in COVID-19 patients versus cancer patients, hypothesizing that higher drug exposure in severe COVID-19 cases would enhance treatment outcomes.
- Results indicated that COVID-19 patients had significantly higher imatinib concentrations than cancer patients, with certain exposure parameters showing significant associations with clinical outcomes, thereby suggesting that higher drug levels could improve recovery metrics in COVID-19 patients.
Article Synopsis
- Imatinib was found to reduce 90-day mortality in hospitalized COVID-19 patients, but how it does so biologically is still unclear.
- A study analyzed how changes in specific biological markers due to imatinib influenced mortality rates and recognized three different biological subphenotypes among patients.
- The beneficial effects of imatinib were linked to changes in several biomarkers, particularly in patients with increased levels of surfactant protein D, indicating specific immune responses and endothelial dysfunction.
Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID - imatinib study.
CPT Pharmacometrics Syst Pharmacol
December 2021
This study aimed to determine whether published pharmacokinetic (PK) models can adequately predict the PK profile of imatinib in a new indication, such as coronavirus disease 2019 (COVID-19). Total (bound + unbound) and unbound imatinib plasma concentrations obtained from 134 patients with COVID-19 participating in the CounterCovid study and from an historical dataset of 20 patients with gastrointestinal stromal tumor (GIST) and 85 patients with chronic myeloid leukemia (CML) were compared. Total imatinib area under the concentration time curve (AUC), maximum concentration (C ) and trough concentration (C ) were 2.
View Article and Find Full Text PDFBackground: The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental and early clinical data suggest that the tyrosine-kinase inhibitor imatinib reverses pulmonary capillary leak.
Methods: This randomised, double-blind, placebo-controlled, clinical trial was done at 13 academic and non-academic teaching hospitals in the Netherlands.
Background: Early detection/prediction of flare-ups in asthma, commonly triggered by viruses, would enable timely treatment. Previous studies on exhaled breath analysis by electronic nose (eNose) technology could discriminate between stable and unstable episodes of asthma, using single/few time-points. To investigate its monitoring properties during these episodes, we examined day-to-day fluctuations in exhaled breath profiles, before and after a rhinovirus-16 (RV16) challenge, in healthy and asthmatic adults.
View Article and Find Full Text PDF